# Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis

> **NCT05947669** · PHASE3 · RECRUITING · sponsor: **Odense University Hospital** · enrollment: 195 (estimated)

## Conditions studied

- Colitis

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Methylprednisolone
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT05947669
- **Lead sponsor:** Odense University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-22
- **Primary completion:** 2026-09
- **Final completion:** 2028-09
- **Target enrollment:** 195 (ESTIMATED)
- **Last updated:** 2023-08-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05947669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05947669, "Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05947669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*